Literature DB >> 25215041

Function of the CaMKII-ryanodine receptor signaling pathway in rabbits with left ventricular hypertrophy and triggered ventricular arrhythmia.

Jun Ke1, Xing Xiao2, Feng Chen1, Li He3, Mu-Sen Dai1, Xiao-Ping Wang1, Bing Chen1, Min Chen1, Cun-Tai Zhang2.   

Abstract

BACKGROUND: Calcium calmodulin-dependent kinase II (CaMKII) can be more active in patients with left ventricular hypertrophy (LVH), which in turn causes phosphorylation of ryanodine receptors, resulting in inactivation and the instability of intracellular calcium homeostasis. The present study aimed to determine the effect of CaMKII-ryanodine receptor pathway signaling in rabbits with left ventricular hypertrophy and triggered ventricular arrhythmia.
METHODS: Forty New Zealand rabbits were randomized into four groups (10 per group): sham group, LVH group, KN-93 group (LVH+KN-93), and ryanodine group (LVH+ryanodine). Rabbits in the LVH, KN-93, and ryanodine groups were used to establish a left ventricular hypertrophy model by the coarctation of the abdominal aorta, while those in the sham group did not undergo the coarctation. After eight weeks, action potentials (APs) were recorded simultaneously in the endocardium and epicardium, and a transmural electrocardiogram (ECG) was also recorded in the rabbit left ventricular wedge model. Drugs were administered to the animals in the KN-93 and ryanodine groups, and the frequency of triggered APs and ventricular tachycardia was recorded after the rabbits were given isoprenaline (1 μmol/L) and high-frequency stimulation.
RESULTS: The frequency (animals/group) of triggered APs was 0/10 in the sham group, 10/10 in the LVH group, 4/10 in the KN-93 group, and 1/10 in the ryanodine group. The frequencies of ventricular tachycardia were 0/10, 9/10, 3/10, and 1/10, respectively. The frequencies of polymorphic ventricular tachycardia or ventricular fibrillation were 0/10, 7/10, 2/10, and 1/10, respectively. The frequencies of triggered ventricular arrhythmias in the KN-93 and ryanodine groups were much lower than those in the LVH group (P<0.05).
CONCLUSIONS: KN-93 and ryanodine can effectively reduce the occurrence of triggered ventricular arrhythmia in rabbits with LVH. The CaMKII-ryanodine signaling pathway can be used as a new means of treating ventricular arrhythmia.

Entities:  

Keywords:  CaMKII; Left ventricular hypertrophy; Ryanodine receptors; Signaling transduction pathway; Triggered action potential; Ventricular arrhythmia

Year:  2012        PMID: 25215041      PMCID: PMC4129820          DOI: 10.5847/wjem.j.issn.1920-8642.2012.01.012

Source DB:  PubMed          Journal:  World J Emerg Med        ISSN: 1920-8642


  31 in total

1.  Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure.

Authors:  Ralph J van Oort; Mark D McCauley; Sayali S Dixit; Laetitia Pereira; Yi Yang; Jonathan L Respress; Qiongling Wang; Angela C De Almeida; Darlene G Skapura; Mark E Anderson; Donald M Bers; Xander H T Wehrens
Journal:  Circulation       Date:  2010-11-15       Impact factor: 29.690

2.  Devereux formula for left ventricular mass--be careful to use the right units of measurement.

Authors:  Fahim H Jafary
Journal:  J Am Soc Echocardiogr       Date:  2007-06       Impact factor: 5.251

3.  Regulation of ryanodine receptors in the heart.

Authors:  Stephan Lehnart; Andrew R Marks
Journal:  Circ Res       Date:  2007-10-12       Impact factor: 17.367

4.  CaM kinase augments cardiac L-type Ca2+ current: a cellular mechanism for long Q-T arrhythmias.

Authors:  Y Wu; L B MacMillan; R B McNeill; R J Colbran; M E Anderson
Journal:  Am J Physiol       Date:  1999-06

Review 5.  Innovative approaches to anti-arrhythmic drug therapy.

Authors:  Stanley Nattel; Leif Carlsson
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

6.  Accelerated development of pressure overload-induced cardiac hypertrophy and dysfunction in an RyR2-R176Q knockin mouse model.

Authors:  Ralph J van Oort; Jonathan L Respress; Na Li; Corey Reynolds; Angela C De Almeida; Darlene G Skapura; Leon J De Windt; Xander H T Wehrens
Journal:  Hypertension       Date:  2010-02-15       Impact factor: 10.190

Review 7.  Cellular basis for triggered ventricular arrhythmias that occur in the setting of compensated hypertrophy and heart failure: considerations for diagnosis and treatment.

Authors:  Gudrun Antoons; Avram Oros; Virginie Bito; Karin R Sipido; Marc A Vos
Journal:  J Electrocardiol       Date:  2007 Nov-Dec       Impact factor: 1.438

8.  RyR2 mutations linked to ventricular tachycardia and sudden death reduce the threshold for store-overload-induced Ca2+ release (SOICR).

Authors:  Dawei Jiang; Bailong Xiao; Dongmei Yang; Ruiwu Wang; Philip Choi; Lin Zhang; Heping Cheng; S R Wayne Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-20       Impact factor: 11.205

Review 9.  Calcium cycling proteins in heart failure, cardiomyopathy and arrhythmias.

Authors:  Susumu Minamisawa; Yoji Sato; Myeong-Chan Cho
Journal:  Exp Mol Med       Date:  2004-06-30       Impact factor: 8.718

10.  Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia.

Authors:  Marina Cerrone; Sami F Noujaim; Elena G Tolkacheva; Arkadzi Talkachou; Ryan O'Connell; Omer Berenfeld; Justus Anumonwo; Sandeep V Pandit; Karen Vikstrom; Carlo Napolitano; Silvia G Priori; José Jalife
Journal:  Circ Res       Date:  2007-09-13       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.